Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | PREP | P48147 | 4/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524788 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL2447790 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL12094625 | 1.00 | CHRM2 (0.68) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL30777191 | 0.87 | CHRM2 (0.64) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL19336739 | 0.87 | CHRM2 (0.64) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL22126741 | 0.87 | CHRM2 (0.64) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL372080 | 0.87 | CHRM2 (0.64) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL16122496 | 0.87 | CHRM2 (0.64) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL24448818 | 0.87 | CHRM1 (0.68) | CHRM2CHRM1CHRM3NR1H2PREP | |
| SCHEMBL25962276 | 0.87 | CHRM1 (0.68) | CHRM2CHRM1CHRM3NR1H2PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2022232383-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| CN-114206872-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists | 百济神州有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220017504-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2021023105-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS TLR8 AGONIST | 百济神州有限公司 | 2021-02-11 | — | — | WO | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-9902738-B2 | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-02-27 | — | — | US | disclosed |
| US-9856262-B2 | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-7276521-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070129396-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED | 2007-06-07 | — | — | US | disclosed |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1732923-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099706-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6194438-B1 | ANTITUMOR AGENTS; ANTICANCER AGENTS; FARNESYL-PROTEIN TRANSFERASE INHIBITOR | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| EP-1006113-A1 | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth | Pfizer Products Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | CHRM2 1646/4885CHRM1 666/4885CHRM3 1650/4885 |
| US-20220017504-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM4, CHRM2 | CHRM2 3/4885CHRM1 1/4885CHRM3 5/4885 |
| US-20070129396-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | CHRM2 3/4885CHRM1 19/4885CHRM3 1/4885 |
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | CHRM2 3303/4885CHRM1 4128/4885CHRM3 3526/4885 |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | CHRM3, CHRNA7, CHRNA2 | CHRM2 7/4885CHRM1 19/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.